
    
      This was a two stage, randomized, controlled study of cancer patients undergoing or planning
      to undergo chemotherapy. After stage one, (where patients were exposed to an erythropoiesis
      stimulating agent), patients were randomized to receive either IV iron sucrose or no iron
      supplementation. Patients were then followed to safety and efficacy endpoints.
    
  